Barclays analyst Andrew Mok raised the firm’s price target on Elevance Health to $621 from $584 and keeps an Overweight rating on the shares post the Q1 report. The analyst remains positive on Elevance following its “positively differentiated” cost trend, solid execution in Carelon, and “guarded optimism” in Medicare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Notable companies reporting before tomorrow’s open
- Elevance Health, Inc. (ELV) Q1 Earnings Cheat Sheet
- Centene rises, Molina slides following Floridaâs managed Medicaid awards
- Elevance Health,CD&R in primary care delivery pact, terms undisclosed